The role of nitric oxide in the maintenance of vasoactive balance

Physiological Research

Volumn 56, Issue SUPPL. 2, 2007, Pages

  Pecháňová, Ol'ga ^a,b   Simko F ^c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^c Physics and Informatics   (Slovakia)

Author keywords

Angiotensin ii; Endothelial dysfunction; Endothelins; Hypertension; Nitric oxide; Reactive oxygen species

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL; HOMEOSTASIS; HUMAN; HYPERTENSION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SHORT SURVEY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HOMEOSTASIS; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 38549119899     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (70)

1. ALBERTS GF, PEIFLEY KA, JOHNS A, KLEHA JF, WINKLES JA: Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 269: 10112-10118, 1994.
2. BERNÁTOVÁ I, PECHÁŇOVÁ O, ŠIMKO F: Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 45: 311-316, 1996.
3. BERNÁTOVÁ I, PECHÁŇOVÁ O: NO synthase: biochemical properties and physiologic importance Bratisl Lek Listy 99: 474-482, 1998.
4. BERNÁTOVÁ I, PECHÁŇOVÁ O, ŠIMKO F: Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney Exp Physiol 84: 1095-1105, 1999.
5. BERNÁTOVÁ I, PECHÁŇOVÁ O, PELOUCH V, ŠIMKO F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 32: 177-185, 2000.
6. BERNÁTOVÁ I, BABÁL P, GRUBBS RD, MORRIS M: Acetylcholinesterase inhibition affects cardiovascular structure in mice. Physiol Res 55 (Suppl 1): S89-S97, 2006.
7. BURNSTOCK G: Dual control of local blood flow by purines. Ann N Y Acad Sci 603: 31-44, 1990.
8. ČAČÁNYIOVÁ S, CEBOVÁ M, KUNEŠ J, KRISTEK F: Comparison of vascular function and structure of iliac artery in spontaneously hypertensive and hereditary hypertriglyceridemic rats. Physiol Res 55 (Suppl 1): S73-S80, 2006.
9. CEBOVÁ M, KRISTEK F, KUNEŠ J: Differential remodeling of carotid artery in spontaneously hypertensive and hereditary hypertriglyceridemic rats. Physiol Res 55 (Suppl 1): S81-S87, 2006.
10. CHEN X, TOUYZ RM, RARK JB, SCHIFFRIN EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38: 606-611, 2001.
11. CHU Y, IIDA S, LUND DD, WEISS RM, DIBONA GF, WATANABE Y, FARACI FM, HEISTAD DD: Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Circ Res 92: 461-468, 2003.
12. CORDER R, DOUTHWAITE JA, LEES DM, KHAN NQ, VISEU DOS SANTOS AC, WOOD EG, CARRIER MJ: Endothelin-1 synthesis reduced by red wine. Nature 414: 863-864, 2001.
13. FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980.
14. GHOSH DK, SALERNO JC: Nitric oxide synthases: domain structure and alignment in enzyme function and control. Front Biosci 8: D193-D209, 2003.
15. GOVERS R, RABELINK TJ: Cellular regulation of endothelial nitric oxide synthase. Am J Physiol 280: F193-F206, 2001.
16. HAMILTON CA, BROSNAN MJ, AL-BENNA S, BERG G, DOMINICZAK AF: NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 40: 755-762, 2002.
17. HITOMI H, KIYOMOTO H, NISHIYAMA A: Angiotensin II and oxidative stress. Curr Opin Cardiol 22: 311-315, 2007.
18. HROPOT M, GROTSCH H, KLAUS E, LANGER KH, LINZ W, WIEMER G, SCHOLKENS BA: Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-Schmiedeberg's Arch Pharmacol 350: 646-652, 1994.
19. IGNARRO LJ, BUGA GM, WOOD KS, BYRNS RE, CHAUDHURI G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84: 9265-9269, 1987.
20. KALLIOVALKAMA J, JOLMA P, TOLVANEN JP, KAHONEN M, HUTRI-KAHONEN N, WU X, HOLM P, PORSTI I: Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. Cardiovasc Res 42: 773-782, 1999.
21. KAWADA N, IMAI E, KARBER A, WELCH WJ, WILCOX CS: A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol 13: 2860-2868, 2002.
22. KEDZIERSKI RM, YANAGISAWA M: Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876, 2001.
23. KITAMOTO S, EGASHIRA K, KATAOKA C, USUI M, KOYANAGI M, TAKEMOTO M, TAKESHITA A: Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 18: 1795-1800, 2000.
24. KOJŠOVÁ S, JENDEKOVÁ L, ZICHA J, KUNEŠ J, ANDRIANTSITOHAINA R, PECHÁŇOVÁ O: The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res 55 (Suppl 1): S3-S16, 2006.
25. KOMORI K, VANHOUTTE PM: Endothelium-derived hyperpolarizing factor. Blood Vessels 27: 238-245, 1990.
26. KUNEŠ J, HOJNÁ S, KADLECOVÁ M, DOBEŠ OVÁ Z, RAUCHOVÁ H, VOKURKOVÁ M, LOUKOTOVÁ J, PECHÁŇOVÁ O, ZICHA J: Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res 53 (Suppl 1): S23-S34, 2004.
27. LASSEGUE B, GRIENDLING KK: Reactive oxygen species in hypertension. Am J Hypertens 17: 852-860, 2004.
28. LÜSCHER TF, VANHOUTTE PM: Endothelium-dependent responses in human blood vessels. Trends Pharmacol Sci 9: 181-184, 1988.
29. MAXWELL AJ: Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 6: 101-124, 2002.
30. MONCADA S, GRYGLEWSKI R, BUNTING S, VANE JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
31. MORAWIETZ H, ROHRBACH S, RUECKSCHLOSS U, SCHELLENBERGER E, HAKIM K, ZERKOWSKI HR, KOJDA G, DARMER D, HOLTZ J: Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest 36: 705-712, 2006.
32. MORENO H JR, PIOVESAN NATHAN L, PEREIRA COSTA SK, METZE K, ANTUNES E, ZATZ R, DE NUCCI G: Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur J Pharmacol 287: 93-96, 1995.
33. NOLL G, TSCHUDI M, NAVA E, LÜSCHER TF: Endothelium and high blood pressure. Int J Microcirc 17: 273-279, 1997.
34. PALMER RM, FERRIGE AG, MONCADA S: Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 327: 524-526, 1987.
35. PARK YM, PARK MY, SUH YL, PARK JB: NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 313: 812-817, 2004.
36. PECHÁŇOVÁ O: Contribution of captopril thiol group to the prevention of spontaneous hypertension Physiol Res 56 (Suppl 2): S41-S48, 2007.
37. PECHÁŇOVÁ O, BABÁL P: Activity of some adenine nucleotide degradation enzymes in human atherosclerotic aorta endothelium. Folia Biol (Praha) 39: 188-194, 1993.
38. PECHÁŇOVÁ O, BERNÁTOVÁ I: Effects of long term nitric oxide synthase inhibition in rat cardiovascular system (review). Exp Clin Cardiol 3: 151-157, 1998.
39. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, ŠIMKO F: Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374, 1997.
40. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, BABÁL P: L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res 48: 353-362, 1999.
41. PECHÁŇOVÁ O, BERNÁTOVÁ I, BABÁL P, MARTINEZ MC, KYSELÁ S, ŠTVRTINA S, ANDRIANTSITOHAINA R: Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22: 1551-1559, 2004a.
42. PECHÁŇOVÁ O, DOBEŠOVÁ Z, ČEJKA J, KUNEŠ J, ZICHA J: Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase. J Hypertens 22: 167-173, 2004b.
43. PECHÁŇOVÁ O, MATUŠKOVÁ J, CAPÍKOVÁ D, JENDEKOVÁ L, PAULIS L, ŠIMKO F: Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. Kidney Int 70: 170-176, 2006a.
44. PECHÁŇOVÁ O, REZZANI R, BABÁL P, BERNÁTOVÁ I, ANDRIANTSITOHAINA R: Beneficial effects of Provinols™: cardiovascular system and kidney. Physiol Res 55 (Suppl 1): S17-S30, 2006b.
45. PECHÁŇOVÁ O, ZICHA J, KOJŠOVÁ S, DOBEŠOVÁ Z, JENDEKOVÁ L, KUNEŠ J: Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension. Clin Sci 110: 235-242, 2006c.
46. PECHÁŇOVÁ O, ZICHA J, PAULIS L, ZENEBE W, DOBEŠOVÁ Z, KOJŠOVÁ S, JENDEKOVÁ L, SLÁDKOVÁ M, DOVINOVÁ I, ŠIMKO F, KUNEŠ J: The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 561: 129-136, 2007.
47. PÚZSEROVÁ A, CSIZMADIOVÁ Z, ANDRIANTSITOHAINA R, BERNÁTOVÁ I: Vascular effects of red wine polyphenols in chronic stress-exposed Wistar-Kyoto rats. Physiol Res 55 (Suppl 1): S39-S47, 2006.
48. PÚZSEROVÁ, CSIZMADIOVÁ Z, BERNÁTOVÁ I: Effect of blood pressure on L-NAME-sensitive component of relaxation in adult rats. Physiol Res 56 (Suppl 2): S77-S84, 2007.
49. RAUCHOVÁ H, PECHÁŇOVÁ O, KUNEŠ J, VOKURKOVÁ M, DOBEŠOVÁ Z, ZICHA J: Chronic N-acetylcysteine administration prevents development of hypertension in L-NAME-treated rats: role of reactive oxygen species Hypertens Res 28: 475-482, 2005.
50. RUBANYI GM, BOTELHO LH: Endothelins. FASEB J 5: 2713-2720, 1991.
51. SANDERS PW, CHEN PY, GASTON RS, WARNOCK DG: L-arginine and nitric oxide in the regulation of blood pressure. In: Hypertension: Pathophysiology, Diagnosis, and Management, LARAGH JH, BRENNER BM (eds), Raven Press, New York, 1995, pp 1097-1108.
52. SASE K, MICHEL T: Expression and regulation of endothelial nitric oxide synthase. Trends Cardiovasc Med 7: 28-37, 1997.
53. SCHIFFRIN E: Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 15: 115S-122S, 2002.
54. ŠIMKO F: Is NO the king? Pathophysiological benefit with uncertain clinical impact. Physiol Res 56 (Suppl 2): S1-S6, 2007.
55. ŠIMKO F, ŠIMKO J: Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 48: 1-8, 1999.
56. ŠIMKO F, PECHÁŇOVÁ O, BERNÁTOVÁ I, GVOZDJÁKOVÁ A, KUCHARSKÁ J, HULÍN I, BADA V, TURČÁNI M: Effect of captopril on the development of left ventricular hypertrophy in rabbits with aortic insufficiency. Physiol Res 46: 419-425, 1997.
57. ŠIMKO F, PECHÁŇOVÁ O, BERNÁTOVÁ I, HOLÉCYOVÁ A, ŠIMKO J, SOCHOROVÁ R: Captopril attenuates proteosynthesis in the aorta and decreases endothelaemia in rabbits with aortic insufficiency. Physiol Res 47: 103-107, 1998.
58. ŠIMKO F, ?UPTÁK I, MATUŠKOVÁ J, BABÁL P, PECHÁŇOVÁ O, BERNÁTOVÁ I, HULÍN I: Heart remodeling in the hereditary hypertriglyceridemic rat: effect of captopril and nitric oxide deficiency. Ann NY Acad Sci 967: 454-462, 2002.
59. ŠIMKO F, PECHÁŇOVÁ O, BERNÁTOVÁ I, MATUŠKOVÁ J, LUPTÁK I: Experimental model of NO-deficient hypertension. In: Experimental Models of Diseases J. HOLZEROVÁ (ed), UK Bratislava, 2003, pp 68-71.
60. ŠIMKO F, ?UPTÁK I, MATUŠKOVÁ J, KRAJČIROVIČOVÁ K, SUMBALOVÁ Z, KUCHARSKÁ J, GVOZDJÁKOVÁ A, ŠIMKO J, BABÁL P, PECHÁŇOVÁ O, BERNÁTOVÁ I: L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension. Eur J Clin Invest 35: 362-368, 2005.
61. SLÁDKOVÁ M, KOJŠOVÁ S, JENDEKOVÁ L, PECHÁŇOVÁ O: Chronic and acute effects of different antihypertensive drugs on femoral artery relaxation of L-NAME hypertensive rats. Physiol Res 56 (Suppl 2): S85-S91, 2007.
62. STUEHR DJ: Mammalian nitric oxide synthases. Biochim Biophys Acta 1411: 217-230, 1999.
63. TÖRÖK J, KOPRDOVÁ R, CEBOVÁ M, KUNEŠ J, KRISTEK F: Functional and structural pattern of arterial responses in hereditary hypertriglyceridemic and spontaneously hypertensive rats in early stage of experimental hypertension. Physiol Res 55 (Suppl 1): S65-S71, 2006.
64. TÖRÖK J, MATUŠKOVÁ J, PECHÁŇ OVÁ O, KRAJČIROVIČOVÁ K, ŠIMKO F: Simvastatin, but not L-arginine, improves endothelial function of aorta in hereditary hypertriglyceridemic rats. Physiol Res 56 (Suppl 2): S33-S40, 2007.
65. TOUYZ RM, SCHIFFRIN EL: Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122: 339-352, 2004.
66. VANHOUTTE PM, FELETOU M, TADDEI S: Endothelium-dependent contractions in hypertension. Br J Pharmacol 144: 449-458, 2005.
67. ZHANG Y, HOGG N: S-Nitrosothiols: cellular formation and transport. Free Radic Biol Med 38: 831-838, 2005.
68. ZHOU MS, SCHULMAN IH, RAIJ L: Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 24: 366-378, 2004.
69. ZICHA J, DOBEŠOVÁ Z, KUNEŠ J: Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats. Hypertens Res 29: 1021-1027, 2006a.
70. ZICHA J, PECHÁŇOVÁ O, ČAČ ANYIOVÁ S, CEBOVÁ M, KRISTEK F, TÖRÖK J, ŠIMKO F, DOBEŠOVÁ Z, KUNEŠ J: Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res 55 (Suppl 1): S49-S63, 2006b.